Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
FK UKM 2012
oUTLINE
Biochemistry and physiology Laboratory evaluation of adrenocortical function Hyperfunction of the adrenal cortex
Cushings syndrome Aldosteronism Virilization
PHYSIOLOGY
Adrenal cortex 1. Glucocorticoids (cortisol, corticosterone) Modulating intermediary metabolism and immune responses 2. Mineralocorticoids (aldosterone, deoxycorticosterone) Regulating blood pressure, vascular volume, and electrolytes 3. Adrenal androgens (DHEA, DHEAS) Secondary sexual characteristics
Steroid structure
Steroid transport
Plasma cortisol 1. Protein bound cortisol Cortisol binding globulin (CBG) or transcortin High affinity, low capacity in inflammation in high estrogen state 70% exogenous cortisol binds to CBG Cortisol binding albumin
Steroid transport
2. Free cortisol ( < 5 %) Filterable at the glomerulus 3. Cortisol metabolites Filterable at the glomerulus Inactive biologically Bind weakly to circulating plasma protein Plasma aldosterone
Circulating aldosterone ( 50%) Protein bound aldosterone (<< than cortisol)
Adrenal androgens
Daily secretion between 15 30 mg In male, 2/3 of androgen derived from the adrenal, 1/3 from the testicular In female, all androgen derived from the adrenal
Gluco corticoid
GR
MR
Mineralocorticoid Glucocorticoid
Acth physiology
Glucocorticoid physiology
Regulation of carboydrate metabolism Promotes hepatic glucose synthesis (gluconeogenesis) and hepatic glycogen content Antagonizing the secretion & action of insulin Inhibiting peripheral glucose uptake
Glucocorticoid physiology
Regulation of protein metabolism in protein breakdown & nitrogen excretion (catabolic) Inhibition of protein synthesis & amino acid uptake Mobilization of glycogenic amino acid precursors from peripheral supporting structures Stimulate the synthesis of certain enzymes (tyrosine aminotransferase, tryptophan pyrrolase)
Glucocorticoid physiology
Regulation of lipid metabolism
Enhancing the activation of cellular lipase by lipidmobilizing hormones (cathecholamines, pituitary peptides) Decreasing the peripheral adipose tissue mass & expanding the abdominal & interscapular fat
Glucocorticoid physiology
Anti-inflammatory Modulate the immune response via immune - adrenal axis Release of leukocytes from BM Depletion of circulating eosinophils & lymphoid tissue (T cells) via redistribution impairs CMI Inhibit the production & action of inflammatory mediators (lymphokine, phospholipase A2, IFN, IL-1, IL-6, IL-2, bradykinin, PAF, serotonin)
Glucocorticoid physiology
Regulate the extracellular fluid volume Retarding the migrating of water into cells Promoting renal water excretion via vasopressin suppression, in GFR, direct action on the renal tubule Weak mineralocorticoid like properties High doses renal Na reabsorption and K excretion
Glucocorticoid physiology
Influence behaviour & emotional Suppresses the secretion of pituitary POMC & its derivative peptides (ACTH, endorphin) Suppresses the secretion of hypothalamic CRH & vasopressin
Glucocorticoid physiology
Trigger of cortisol secretion Physical stress (trauma, surgery, exercise) Psychological stress (anxiety, depression) Physiologic states (hypoglycemia, fever) Mechanism are not understood
Mineralocorticoid physiology
Effects on epithelia cells (renal CCD, salivary ducts, sweat glands, GIT) Major regulators of ECFV & K+ metabolism gene expression for Na pump & K channel directly the number & activity of Na channels via a complex process
Mineralocorticoid physiology
Effects on nonepithelial cells (neurons, myocytes, endothelial cells, vascular smoothmuscle cells)
No modification of Na-K homeostasis Modify the expression of collagen genes controlling TGF No MR protection by 11-HSD 2 enzyme in myocardium & brain cortisol >> activates MR
Mineralocorticoid physiology
Androgen physiology
DHEA, androstenedione, 11hydrosyandrostenedione Regulate male secondary sexual characteristic Cause virilizing symptoms in women Regulated by ACTH not by gonadotropins
BLOOD LEVELS
Peptide ACTH plasma Cicardian rythm Pulsatile secretion rapid fluctuations Angiotensin II Vary diunarlly Influenced by dietary Na & K intakes Influenced by posture
BLOOD LEVELS
Peripheral Plasma Renin Activity (PRA) Measurement of generated angiotensin I Depends on the presence of sufficient angiotensinogen in the plasma as substrate Depends on the Na intake & ambulation Diurnal rythm (peak in a.m, nadir in p.m) Plasma active renin Easier Not dependent on endogenous substrate concentration Depends on the Na intake
BLOOD LEVELS
Steroids Plasma cortisol Secreted episodically (peak in a.m, nadir in p.m) Plasma aldosterone Secreted episodically (peak in a.m, nadir in p.m) Increased by dietary K loading, Na restriction, upright posture
BLOOD LEVELS
DHEA sulfate Formed in the gonads very little Half life of 7 9 hours Reflects both DHEA production and sulfatase activity
Urine levels
Assessment of glucocorticoid secretion Urinary free cortisol Rate of excretion >> in the daytime than at night Reflecting changes in the levels of unbound cortisol Urinary 17 ketosteroid Originate in either the adrenal gland (women 90%) or the gonad (men 60 %) Highest value in young adults Urinary creatinine should simultaneously measured
Stimulation test
Tests of glucocorticoid reserve (Rapid ACTH stimulation test)
Cortisol Level
30
60 Time
Normal response : cortisol level > 18 g/dL or increment of > 7 g/dL above baseline
Stimulation test
Test of Mineralocorticoid reserve & stimulation of RAS
Sodium
Suppression test
Tests of pituitary adrenal suppressibility (overnight Dexamethasone suppression test)
Dexamethasone 1 mg p.o @ midnight
Dexamethasone 0.5 mg q6h p.o + Urine specimen 24 hours 2 consecutive days Normal response : Urine free cortisol : < 10 g/day Plasma cortisol : < 5 g/dL
Suppression test
Tests of Mineralocorticoid suppressibility
IV infusion of 500 ml/h of NaCl for 4 hours High Na diet for 3 days + Fludrocortisone 0.2 mg bid
Plasma aldosterone : < 8 ng/dL, in Na-restricted diet < 5 ng/dL, in normal Na diet
Metyrapone test
Inhibition 11-HDS in adrenal impair conversion of 11 deoxycortisol to cortisol Metyrapone 750 mg po q4h over 24 hrs Normal response : plasma 11-deoxycortisol > 7g/dL; plasma ACTH > 75 pg/mL
Pituitary corticotroph test Bolus injection of ovine CRH 1 g/kg IV Normal response : plasma ACTH increment 40 pg/mL after 1 hour. Rapid ACTH test Distinguish the primary & secondary AI 25 U Cosyntropine IV or IM measurement of plasma cortisol & aldosterone before, 30, 60 after. Normal response : Plasma cortisol abnormal in both AI Plasma aldosterone 5 ng/dL in secondary AI
Excess cortisol Cushings syndrome Excess aldosterone aldosteronism Excess adrenal androgens adrenal virilism
Adrenal virilism
Acne, hirsutism, oligo/amenorrhea Less frequent
FNA is not useful to distinguish between benign & malignant primary adrenal tumors
Aldosteronism : definition
A syndrome associated with hypersecretion of the mineralocorticoid aldosterone Classification
Primary aldosteronism With an adrenal tumor Without an adrenal tumor Secondary aldosteronism
Primary aldosteronism
With an adrenal tumor (Conns syndrome) Usually unilateral adenoma Small in size Benign character Women > 2x men Age : 30 50 years old Present in 1 % of unselected hypertensive px
Primary aldosteronism
Without an adrenal tumor 80 % of px with primary aldosteronism Bilateral cortical nodular hyperplasia Idiopathic hyperaldosteronism DD/ : low renin essential hypertension Hypokalemia is unlikely, lower level of aldosterone, less radiologic evidence for adrenal pathology
Potassium depletion
Muscle weakness, fatigue
Metabolic alkalosis
H+ ion loss into the urine Migration into K+ depleted cells capacity of the proximal convoluted tubule to reabsorb filtered bicarbonate
Hypomagnesemia
Severe hypokalemia (< 3 meq/L)
Elevated testosterone
Mixed syndromes
Virilization : definition
A condition in which androgen levels are sufficiently high to cause additional signs and symptoms such as deepening of the voice, breast atrophy, increased muscle bulk, clitoromegaly, and increased libido
Hirsutism : definition
Excessive male-pattern hair growth, affects approximately 10% of women, represents a variation of normal hair growth, but rarely it is a harbinger of a serious underlying condition.
Virilization : ETIOLOGY
Gonadal hyperandrogenism
Ovarian hyperandrogenism Polycystic ovary syndrome/functional ovarian hyperandrogenism Ovarian steroidogenic blocks Syndromes of extreme insulin resistance Ovarian neoplasms
Virilization : ETIOLOGY
Adrenal hyperandrogenism
Premature adrenarche Functional adrenal hyperandrogenism Congenital adrenal hyperplasia (nonclassic and classic) Abnormal cortisol action/metabolism Adrenal neoplasms
Virilization : ETIOLOGY
Other endocrine disorders
Cushing's syndrome Hyperprolactinemia Acromegaly
Virilization : ETIOLOGY
Pregnancy-related hyperandrogenism
Hyperreactio luteinalis Thecoma of pregnancy
Drugs
Androgens Oral contraceptives containing androgenic progestins Minoxidil Phenytoin Diazoxide Cyclosporine
True hermaphroditism
Virilization : treatment
Nonpharmacologic
1. Bleaching 2. Depilatory (shaving, chemical treatment) 3. Epilatory (plucking, waxing, electrolysis, laser)
Virilization : treatment
Pharmacologic
1. Suppression of adrenal and/or ovarian androgen production 2. Enhancement of androgen binding to plasma binding proteins 3. Impairment of the peripheral conversion of androgen precursors to active androgen 4. Inhibition of androgen action at the target tissue
Virilization : treatment
Combination estrogen progestin
production of ovarian androgens by LH suppression DHEAS by reducing ACTH level Direct, dose dependent suppressive effect on sebaceous cell function Progestin component (norgestrel, levonorgestrel) attenuate the estrogen induced increase in SBHG Contraindicated in thromboembolic disease history, risk of breast Ca Improve the extent of acne up to 70% Effect on hair growth after 9 12 months Improve the hirsutism (20%)
Virilization : treatment
Glucocorticoids
Mainstay of treatment in px with CAH Adrenal androgens are more sensitive than cortisol to the suppressive effects of glucocorticoid Dexamethasone 0.2 0.5 mg or Prednisone 5 10 mg at bedtime
Virilization : treatment
Cyproterone acetate
Prototypic of antiandrogen Competitive inhibition of the binding of testosterone & DHT to the androgen receptor Enhance the metabolic clearance of testosterone by inducin hepatic enzymes Dose : 50 100 mg daily on days 1 15 and ethinyl estradiol 50 mcg on days 5 26 of the menstrual cycle Side effects : irregular uterine bleeding, nausea, headache, fatigue, weight gain, decreased libido
Virilization : treatment
Spironolactone
A weak antiandrogen, mineralocorticoid antagonist Dose : 100 200 mg daily Side effects : hyperkalemia, hypotension, pregnancy, irregular menstruation May be combined with estrogen
Virilization : treatment
Flutamide A potent nonsteroidal antiandrogen in treating hirsutism Side effect : hepatocellular dysfunction
( Addisons disease)
Exogenous steroid
Low ACTH, low cortisol, abnormal ACTH & metyrapone responses
IV infusion of D5NaCl rapidly Bolus IV infusion of 100 mg hydrocortisone followed by a continuous infusion at a rate of 10 mg / hour Alternative approach : Bolus hydrocortisone 100 mg IV q6h Vasoconstrictor (Dopamine) in extreme conditions
Hypoaldosteronism : etiology
Isolated aldosterone deficiency accompanied by normal cortisol production in association with :
Hyporeninism Inherited biosynthetic defect Postoperative aldosterone secreting adenomectomy During protracted heparin administration Pretectal disease of the CNS Severe postural hypotension
Hypoaldosteronism : pathogenesis
1. Hyporeninemic hypoaldosteronism
Renal disease Autonomic neuropathy ECFV expansion Defective conversion of renin precursors to active renin
Hypoaldosteronism : pathogenesis
2. Hypereninemic hypoaldosternoism
Severely ill patient High mortality (80 %) Hyperkalemia (-) Adrenal necrosis (uncommon) Shift in steroidogenesis from mineralocorticoids to glucocorticoids due to prolonged ACTH stimulation
Hypoaldosteronism : diagnosis
Serum Potassium Pseudohyperkalemia -Hemolysis -Thrombocytosis ACTH stimulation test Abnormal Normal Renin & aldosterone stimulation test Hyperreninemic hypoaldosteronism
Addisons disease
Hyporeninemic hypoaldosteronism
Hypoaldosteronism : treatment
Fludrocortisone 0.05 0.15 mg PO daily Adequate salt intake (150 200 meq) daily Alternative approach : reduce salt intake + administration of furosemide